HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Antioxidant and metabolic therapy of lower limb chronic obliterative arterial disease].

Abstract
Metabolic therapy is one of several therapeutic strategies that can be used in patients with lower limb chronic obliterative arterial disease (COAD). Tanakan (EGb76) has demonstrated high efficiency and safety in 9 controlled clinical trials and author's clinical series in patients with lower limb COAD. Improvement with significant increase of pain-free walking distance and beneficial safety profile was observed in all cases. Tanakan (EGb76) is highly effective conventional therapeutic agent for memory and attention disorders, dizziness and balance disturbances in adults and elderly patients. Given a common concomitance of these disorders and lower limb COAD, Tanakan can be recommended as a drug of choice for treatment of chronic obliterative arteriopathy.
AuthorsV M Koshkin, S V Murav'ev, L V Dadova, P B Kalashov
JournalAngiologiia i sosudistaia khirurgiia = Angiology and vascular surgery (Angiol Sosud Khir) Vol. 12 Issue 3 Pg. 29-32 ( 2006) ISSN: 1027-6661 [Print] Russia (Federation)
PMID17641611 (Publication Type: Journal Article, Review)
Chemical References
  • Antioxidants
  • Plant Extracts
  • Vasodilator Agents
  • Ginkgo biloba extract
Topics
  • Antioxidants (therapeutic use)
  • Arteriosclerosis Obliterans (drug therapy, physiopathology)
  • Atherosclerosis
  • Chronic Disease
  • Ginkgo biloba
  • Humans
  • Lower Extremity (blood supply)
  • Plant Extracts (therapeutic use)
  • Vasodilator Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: